ZyVersa Therapeutics, Inc., a clinical-stage biopharmaceutical company, has filed a prospectus related to the offer and resale of up to 478,600 shares of common stock by selling stockholders. These shares are issuable upon the exercise of Series A-1 and Series B-1 warrants acquired by the selling stockholders in a private placement that closed on August 2, 2024. ZyVersa will not sell any securities under this prospectus nor receive proceeds from the stock sales by the selling stockholders. However, if all warrants are exercised in cash at the exercise price of $3.46 per share, ZyVersa may receive approximately $1,655,956 in gross proceeds. The selling stockholders may sell the shares at varying prices and methods, including on the open market or through private transactions. The company...Show More

ZyVersa Therapeutics, Inc., a clinical-stage biopharmaceutical company, has filed a prospectus related to the offer and resale of up to 478,600 shares of common stock by selling stockholders. These shares are issuable upon the exercise of Series A-1 and Series B-1 warrants acquired by the selling stockholders in a private placement that closed on August 2, 2024. ZyVersa will not sell any securities under this prospectus nor receive proceeds from the stock sales by the selling stockholders. However, if all warrants are exercised in cash at the exercise price of $3.46 per share, ZyVersa may receive approximately $1,655,956 in gross proceeds. The selling stockholders may sell the shares at varying prices and methods, including on the open market or through private transactions. The company has undergone reverse-stock-splits on December 4, 2023, and April 25, 2024, and the share information in the prospectus has been adjusted accordingly. ZyVersa's common stock is listed on The Nasdaq Stock Market under the symbol 'ZVSA'. The last reported sale price of ZyVersa's common stock was $2.77 per share as of August 30, 2024. The prospectus also outlines the risks associated with investing in ZyVersa's securities, including the company's ability to continue as a going concern and the need for additional capital to fund its operations and development programs.